168 related articles for article (PubMed ID: 16906022)
1. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
[TBL] [Abstract][Full Text] [Related]
2. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
3. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
[TBL] [Abstract][Full Text] [Related]
4. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
[TBL] [Abstract][Full Text] [Related]
5. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
[TBL] [Abstract][Full Text] [Related]
6. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
7. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels.
Gerloff T; Schaefer M; Mwinyi J; Johne A; Sudhop T; Lütjohann D; Roots I; von Bergmann K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Apr; 373(1):45-50. PubMed ID: 16568260
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
9. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
[TBL] [Abstract][Full Text] [Related]
10. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
Zhang W; He YJ; Gan Z; Fan L; Li Q; Wang A; Liu ZQ; Deng S; Huang YF; Xu LY; Zhou HH
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1240-4. PubMed ID: 17973861
[TBL] [Abstract][Full Text] [Related]
11. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
12. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
[TBL] [Abstract][Full Text] [Related]
13. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
de Jong FA; Mathijssen RH; Xie R; Verweij J; Sparreboom A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4068-71. PubMed ID: 15217940
[TBL] [Abstract][Full Text] [Related]
14. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.
Tornio A; Vakkilainen J; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2015 Aug; 25(8):382-7. PubMed ID: 26020121
[TBL] [Abstract][Full Text] [Related]
15. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
16. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
17. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
Choi CI; Lee YJ; Lee HI; Kim BH; Kim MJ; Jang CG; Bae JW; Lee SY
Xenobiotica; 2012 May; 42(5):496-501. PubMed ID: 22077103
[TBL] [Abstract][Full Text] [Related]
18. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
Mwinyi J; Johne A; Bauer S; Roots I; Gerloff T
Clin Pharmacol Ther; 2004 May; 75(5):415-21. PubMed ID: 15116054
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
